Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy
October 14, 2026 | HEOR, Market Access, Orphan Drugs, Payers, access and pricing, payer engagement, payer research, rpr
In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will reshape orphan medicine development, assessment, and launch.
How will EU General Pharmaceutical Legislation (GPL) impact orphan medicine development and assessment?
Genesis Research Group continues to leverage RPR, its stakeholder engagement solution, to capture unique insights which they can share with senior industry professionals.
In the third issue of The Vector, they asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will reshape orphan medicine development, assessment and launch.
We learn:
- Why breakthrough status invites scrutiny, not a premium: how payers plan to negotiate differently with higher tier orphan products.
- The evidence hierarchy that payers will reward most when randomized trials are not feasible
- A country-by-country view: why France is the most skeptical market, Spain the most polarized, Italy the most positive, and why the UK could become an early-launch market for rare diseases
- The policy collision ahead: how US MFN pricing and EU reform pull launch decisions in opposite directions, and why the next 12–24 months matter.
Pharma, biotech, academic, and representatives of industry bodies, can access The Vector Issue 3 by subscribing for free via the link below.
Subscribers can also access previous payer surveys on whether AI is beginning to shape coverage decisions workflows and how most-favored nation pricing is perceived to alter pricing, reimbursement, and access dynamics.
Access and subscribe to The Vector
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy
In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will…
On GLOBE Final Rule
The publication of the GLOBE Final Rule provides important clarity on the administration’s approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally….
Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.
On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…